

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

Brilliant Violet 605(TM) anti-mouse CD279 (PD-1)

RRID:AB_11125371

Type: Antibody

Proper Citation

BioLegend Cat# 135219, RRID:AB_11125371

Antibody Information

URL: http://antibodyregistry.org/AB_11125371

Proper Citation: BioLegend Cat# 135219, RRID:AB_11125371

Target Antigen: CD279

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-mouse CD279 (PD-1)

Description: This monoclonal targets CD279

Target Organism: mouse

Clone ID: Clone 29F.1A12

Antibody ID: AB_11125371

Vendor: BioLegend

Catalog Number: 135219

Alternative Catalog Numbers: 135220

Record Creation Time: 20250819T232734+0000

Record Last Update: 20250820T052418+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-mouse CD279 (PD-1).

No alerts have been found for Brilliant Violet 605(TM) anti-mouse CD279 (PD-1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Marco S, et al. (2026) Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. *Cancer cell*, 44(5), 995.

Gao Y, et al. (2025) Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy. *Cell reports. Medicine*, 6(11), 102434.

Yong CSM, et al. (2025) IL-2 immunotherapy rescues irradiation-induced T cell exhaustion in mouse colon cancer. *iScience*, 28(6), 112639.

Diers AR, et al. (2025) Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy. *Cancer research communications*, 5(2), 327.

Xiao J, et al. (2025) Uridine depletion impairs CD8⁺ T cell antitumor activity through N-glycosylation. *Cell metabolism*.

Jaeger-Ruckstuhl CA, et al. (2024) Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. *Immunity*, 57(2), 287.

Guak H, et al. (2024) Transcriptional programming mediated by the histone demethylase KDM5C regulates dendritic cell population heterogeneity and function. *Cell reports*, 43(8), 114506.

Marx AF, et al. (2023) The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1⁺ CD8⁺ T cells in chronic viral infection. *Immunity*, 56(4), 813.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. *Cancer cell*, 41(5), 837.

Best SA, et al. (2022) Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer. *Cell metabolism*, 34(6), 874.

- Lu Z, et al. (2022) ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes. *Cell metabolism*, 34(9), 1342.
- Kersten K, et al. (2022) Spatiotemporal co-dependency between macrophages and exhausted CD8⁺ T cells in cancer. *Cancer cell*, 40(6), 624.
- Wørzner K, et al. (2021) Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. *EBioMedicine*, 63, 103197.
- Wen J, et al. (2020) CD4⁺ T Cells Cross-Reactive with Dengue and Zika Viruses Protect against Zika Virus Infection. *Cell reports*, 31(4), 107566.
- Sandu I, et al. (2020) Landscape of Exhausted Virus-Specific CD8 T Cells in Chronic LCMV Infection. *Cell reports*, 32(8), 108078.
- Ringel AE, et al. (2020) Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. *Cell*, 183(7), 1848.
- Marro BS, et al. (2019) Discovery of Small Molecules for the Reversal of T Cell Exhaustion. *Cell reports*, 29(10), 3293.
- Srivastava S, et al. (2019) Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. *Cancer cell*, 35(3), 489.
- Stathopoulou C, et al. (2018) PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells. *Immunity*, 49(2), 247.
- Best SA, et al. (2018) Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment. *Cell metabolism*, 27(4), 935.